



DETECT abstract accepted at World Congress on Endometriosis 2025

London, UK, 14 January 2025. [Serac Healthcare Limited](#) (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that an abstract on the “Detecting Endometriosis expressed integrins using technetium-99m” imaging (DETECT) study, has been accepted for oral presentation at the prestigious 16th [World Congress on Endometriosis](#) taking place from 21-24 May in Sydney, Australia.

[Dr Tatjana Gibbons](#), an investigator on the ongoing study from the [Nuffield Department of Women’s and Reproductive Health](#) at the [University of Oxford](#), will be presenting results from the study which aims to determine the feasibility of detecting endometriosis using ^{99m}Tc-maraciclalide and single-photon emission computed tomography.

Initial findings presented last year have indicated that ^{99m}Tc-maraciclalide has potential as a non-invasive test for superficial peritoneal disease which cannot be detected using existing non-invasive imaging techniques; and in July 2024, ^{99m}Tc-maraciclalide was granted Fast Track Designation as a diagnostic agent for use with SPECT CT for the visualisation and diagnosis of superficial peritoneal endometriosis in women of 16 years and older. The FDA Fast track is intended to facilitate the development and expedite the review of drugs to treat (or in our case, diagnose) serious conditions and fill an unmet medical need. Criteria include improving the diagnosis of a serious condition where early diagnosis results in an improved outcome.

The study, which is now close to completion, is being led by [Professor Christian Becker](#), Co-Director of the Endometriosis CaRe Centre in Oxford, together with [Professor Krina Zondervan](#), Co-Director of the Endometriosis CaRe Centre and Head of Department at the Nuffield Department of Women’s and Reproductive Health, University of Oxford.

-ENDS-

Maraciclalide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.

For more information, please contact:

Serac Healthcare Ltd

www.serachealthcare.com

David Hail, Chief Executive Officer

+44 (0)208 948 0000

info@seraclifesciences.com

Francetta Carr, Communications Director

+44 (0)7711 010820

francettacarr@seraclifesciences.com

Notes to Editors

About Serac Healthcare Ltd

Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis and inflammatory arthritis, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and to deliver earlier and more effective treatment decisions. Serac Healthcare Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

About ^{99m}Tc-maraciclalide

^{99m}Tc-maraciclatiside is a radio-labelled tracer which binds with high affinity to the cell adhesion protein $\alpha_v\beta_3$ integrin and images angiogenesis (new blood vessel formation) which is known to be critical to the establishment and growth of endometriotic lesions.

About the DETECT study

In the DETECT study, women with confirmed or suspected endometriosis who are due to undergo laparoscopy, a key-hole surgical procedure used to assess the organs in the abdomen and pelvis, are imaged with ^{99m}Tc-maraciclatiside before laparoscopic surgery. During surgery, tissue samples with identified endometriosis are collected and analysed to determine the presence of $\alpha_v\beta_3$. The laparoscopic and radiographic findings are compared to determine whether ^{99m}Tc-maraciclatiside holds potential as a novel, non-invasive method of detecting early-stage endometriosis.

The study is jointly sponsored by Oxford Endometriosis CaRe Centre and the Nuffield Department of Women's and Reproductive Health, Oxford University, and funded by Serac Healthcare Ltd who are providing the experimental imaging marker ^{99m}Tc-maraciclatiside. Further details are available on ClinicalTrials.gov [here](#).

About the Nuffield Department of Women's & Reproductive Health, University of Oxford

The Nuffield Department of Women's & Reproductive Health (NDWRH) at the University of Oxford is a global leader in women's health research, dedicated to advancing healthcare through cutting-edge research, clinical studies, and postgraduate education. Established in 1937, the department's work spans a broad range of women's health issues, including reproductive health, perinatal care, cancer, fetal health, pain in women, mental health, and global health. NDWRH strives to make high-quality, evidence-based healthcare accessible to all, with a focus on improving health outcomes for women worldwide.

As part of the University of Oxford, ranked #1 in the Times Higher Education World University Rankings for the eighth consecutive year and #3 in the QS World Rankings, NDWRH is embedded within a globally renowned institution known for its interdisciplinary research and collaborative approach. Oxford's commitment to academic excellence drives the department's pioneering work, addressing complex healthcare challenges and shaping global policies. Our work helps improve the lives of millions, solving real-world problems through an extensive network of partnerships and collaborations, and continues to advance health through innovative, transformative solutions.